Advanced Glycation End-Products Downregulate HoxA9EC through Activation of Nuclear Factor Kappa B by Reciprocal Interaction

2017 ◽  
Vol 54 (4) ◽  
pp. 226-234 ◽  
Author(s):  
Qian-qian Zhu ◽  
Dong-lin Li ◽  
Yang-yan He ◽  
Zi-heng Wu ◽  
Lu Tian ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
Advanced Glycation ◽  
Reciprocal Interaction ◽  
Nuclear Factor Kappa ◽  
Glycation End Products ◽  
End Products

scholarly journals Tropisetron modulates peripheral and central serotonin/insulin levels via insulin and nuclear factor kappa B/receptor for advanced glycation end products signalling to regulate type-2 diabetes in rats

RSC Advances ◽  
2018 ◽  
Vol 8 (22) ◽  
pp. 11908-11920
Author(s):  
Reem Ali Mohamed ◽  
Omneya Galal ◽  
Ahmed Refaat Mohammed ◽  
Hanan Salah El-Abhar
Keyword(s):  
Type 2 Diabetes ◽  
Signaling Pathways ◽  
Advanced Glycation End Products ◽  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
Advanced Glycation ◽  
Insulin Levels ◽  
Glycation End Products ◽  
End Products

Schematic illustration of tropisetron's (5-HT3 antagonist) modulation of the insulin and Wnt/β-catenin signaling pathways both peripherally and centrally in type 2 diabetes.

scholarly journals Renal Protective Role of Xiexin Decoction with Multiple Active Ingredients Involves Inhibition of Inflammation through Downregulation of the Nuclear Factor-κB Pathway in Diabetic Rats

2013 ◽  
Vol 2013 ◽  
pp. 1-15 ◽  
Author(s):  
Jia-sheng Wu ◽  
Rong Shi ◽  
Jie Zhong ◽  
Xiong Lu ◽  
Bing-liang Ma ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Protective Role ◽  
Diabetic Rats ◽  
Partial Least Square ◽  
Nuclear Factor ◽  
Advanced Glycation ◽  
Advanced Glycation End Product ◽  
Glycation End Products ◽  
End Products

In Chinese medicine, Xiexin decoction (XXD) has been used for the clinical treatment of diabetes for at least 1700 years. The present study was conducted to investigate the effective ingredients of XXD and their molecular mechanisms of antidiabetic nephropathy in rats. Rats with diabetes induced by high-fat diet and streptozotocin were treated with XXD extract for 12 weeks. XXD significantly improved the glucolipid metabolism disorder, attenuated albuminuria and renal pathological changes, reduced renal advanced glycation end-products, inhibited receptor for advanced glycation end-product and inflammation factors expression, suppressed renal nuclear factor-κB pathway activity, and downregulated renal transforming growth factor-β1. The concentrations of multiple components in plasma from XXD were determined by liquid chromatography and tandem mass spectrometry. Pharmacokinetic/pharmacodynamic analysis using partial least square regression revealed that 8 ingredients of XXD were responsible for renal protective effects via actions on multiple molecular targets. Our study suggests that the renal protective role of XXD with multiple effective ingredients involves inhibition of inflammation through downregulation of the nuclear factor-κB pathway, reducing renal advanced glycation end-products and receptor for advanced glycation end-product in diabetic rats.

Sign in / Sign up

Export Citation Format

Share Document